Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, has the potential to become the first medication approved for the treatment of patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis.